RE: Of interest ..27 Jun 2018 11:34
The important part of the trial to us is not the adjuvant part as SCLP beats it hands down, the important bit is actually the stats on the pd1 ligand expression on the cancer which has been checked after surgery .
you will see a term RFS
n cancer, the length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer. In a clinical trial, measuring the RFS is one way to see how well a new treatment works. Also called DFS, disease-free survival, and relapse-free survival.
so its these two data sets that are "very" important
In the PD-L1–positive group, the 1-year RFS rate was 77.1% (95% CI, 72.7-80.9) in the pembrolizumab group and 62.6% (95% CI, 57.7-67.0) in the placebo group (HR, 0.54; 95% CI, 0.42-0.69; P <.001). The 18-month RFS rates were 74.2% versus 54.5%, respectively.
Among PD-L1–negative patients, the 1-year RFS rates were 72.2% (95% CI, 58.6-82.0) in the pembrolizumab arm versus 52.2% (95% CI, 38.2-64.5) in the placebo group (HR, 0.47; 95% CI 0.26-0,85; P = .01). The 18-month RFS rates were 60.6% versus 52.2%, respectively.
so this clearly shows that the cancer that expressed PD1 ligand also responded best to treatment .......
SCIB1 and SCIB2 upregualates ... (increase) PD1 ligand on the cancer ......
so again Very clear evidence that SCIB1 as seen in patients induced inflammation which results in up regulation of the PD1 ligand so will have synergy with PD1
You can look at this from every angle and Proof of "process" or "synergy" is every where ....
Sign In
Follow the stocks
